Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16960867 | 0.95 | HPGD (0.42) | HPGDNPC1MAPK1HTTRAB9A | |
| SCHEMBL16961331 | 0.93 | HPGD (0.41) | HPGDNPC1MAPK1HTTRAB9A | |
| SCHEMBL170953 | 0.93 | PTGS2 (0.50) | PTGS2CYP3A4CA2GPR84CA1 | |
| SCHEMBL829394 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1186069 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1187331 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1186650 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1188332 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1186516 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 | |
| SCHEMBL1187072 | 0.91 | PTGS2 (0.52) | PTGS2CYP3A4GPR84ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-07-04 | — | — | US | claimed |
| CN-112742483-B | Catalyst system for ethylene selective oligomerization and preparation and application thereof | 华东理工大学 | 2024-04-02 | — | — | CN | claimed |
| WO-2023196594-A2 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3550657-B1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO LTD (CN) | 2023-06-28 | — | — | EP | claimed |
| WO-2020251247-A1 | NOVEL TRANSITION METAL COMPOUND AND METHOD FOR PREPARING POLYPROPYLENE USING SAME | 주식회사 엘지화학 | 2020-12-17 | — | — | WO | claimed |
| EP-3550657-A1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | Contemporary Amperex Technology Co., Limited (CN) | 2019-10-09 | — | — | EP | claimed |
| US-20190267671-A1 | ELECTROLYTE AND SECONDARY LITHIUM BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2019-08-29 | — | — | US | claimed |
| CN-107033342-A | A kind of preparation method of the solid supported chiral bisoxazoline parts of PEG | 清华大学 | 2017-08-11 | — | — | CN | claimed |
| CN-106632478-A | Chiral bidentate nitrogen-containing phosphine ligands and application thereof in asymmetric catalytic reaction | 武汉凯特立斯科技有限公司 | 2017-05-10 | — | — | CN | claimed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| US-20090044863-A1 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2009-02-19 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| US-20080223444-A1 | Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | GEORGIA TECH RESEARCH CORPORATION | 2008-09-18 | — | — | US | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| US-7161018-B2 | Soluble late transition metal catalysts for olefin oligomerizations II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-01-09 | — | — | US | claimed |
| EP-1513854-B1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS | EXXONMOBIL CHEM PATENTS INC (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2006093965-A2 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2006-09-08 | — | — | WO | claimed |
| WO-2005124453-A2 | PERYLENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2005-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216900-A1 | SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS | FABP7, FFAR1, FABP1 | HPGD 2102/4885NPC1 576/4885MAPK1 1878/4885 |
| US-20080223444-A1 | Perylene Charge-Transport Materials, Methods of Fabrication Thereof, and Methods of Use Thereof | SLC43A1, SLC3A2, SLC16A3 | HPGD 2088/4885NPC1 596/4885MAPK1 4724/4885 |
| US-20090044863-A1 | CORONENE CHARGE-TRANSPORT MATERIALS, METHODS OF FABRICATION THEREOF, AND METHODS OF USE THEREOF | SLC18A3, CORO1C, SLC18A1 | HPGD 1675/4885NPC1 227/4885MAPK1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.